These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37237267)

  • 21. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
    Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
    Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CIDP prognosis in patients with IVIG treatment-related fluctuations.
    Cook M; Pasnoor M; Ajroud-Driss S; Brannagan TH; Dimachkie MM; Allen JA
    Muscle Nerve; 2023 Jan; 67(1):69-73. PubMed ID: 36330716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
    Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
    Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
    Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F
    Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
    Léger JM; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Mielke O; Tackenberg B; Shebl A; Bauhofer A; Zenker O; Merkies IS;
    J Peripher Nerv Syst; 2013 Jun; 18(2):130-40. PubMed ID: 23781960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment.
    Ellrichmann G; Gold R; Ayzenberg I; Yoon MS; Schneider-Gold C
    Ther Adv Neurol Disord; 2017 Feb; 10(2):91-101. PubMed ID: 28382108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
    Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
    Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
    Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
    Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Merkies IS; Kieseier BC
    Eur Neurol; 2016; 75(3-4):199-206. PubMed ID: 27077919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective analysis of disability and quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Bozovic I; Peric M; Arsic Azanjac A; Palibrk A; Bulatovic I; Aleksic D; Peric S; Basta I
    Qual Life Res; 2021 Sep; 30(9):2573-2579. PubMed ID: 33830457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins.
    Lawley A; Seri S; Rajabally YA
    Clin Neurophysiol; 2019 Oct; 130(10):1743-1749. PubMed ID: 31400577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study.
    Merkies IS; Hughes RA; Donofrio P; Bril V; Dalakas MC; Hanna K; Hartung HP; Latov N; van Doorn PA; Deng C;
    J Peripher Nerv Syst; 2010 Sep; 15(3):208-15. PubMed ID: 21040143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.
    Rajabally YA; Ouaja R; Kasiborski F; Pujol S; Nobile-Orazio E
    Muscle Nerve; 2022 Nov; 66(5):562-567. PubMed ID: 36057106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
    Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
    Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy.
    Kuitwaard K; van den Berg LH; Vermeulen M; Brusse E; Cats EA; van der Kooi AJ; Notermans NC; van der Pol WL; van Schaik IN; van Nes SI; Hop WC; van Doorn PA
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1374-9. PubMed ID: 20587484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octagam
    Wietek S
    Neurodegener Dis Manag; 2018 Aug; 8(4):227-231. PubMed ID: 29517417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.